About Echo

Echo Therapeutics is focused on transdermal continuous glucose montioring (tCGM) systems for people with diabetes and advanced topical reformulations of FDA-approved specialty pharmaceuticals.

Echo's Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system in development for people with diabetes and for use in hospital critical care units. Symphony includes the Prelude™ SkinPrep System that incorporates Echo's patented feedback mechanism for optimal skin ablation control and its non-invasive, continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing for people with diabetes and for use in hospital critical care settings with technology designed to assist clinical professionals, improve patient compliance and achieve better overall glucose control.

Echo is leveraging its patented AzoneTS™ transdermal drug reformulation technology to build a pipeline of novel topical reformulations of FDA-approved products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA's Section 505(b)(2) guidelines. Durhalieve™, Echo's lead AzoneTS drug candidate, is an AzoneTS topical reformulation of triamcinolone acetonide. Echo has submitted a New Drug Application (NDA) to the FDA covering Durhalieve as a new, proprietary treatment for corticosteroid responsive dermatoses. Echo is planning to submit an Investigational New Drug (IND) application to the FDA to commence Phase 2 clinical development of Durhalieve for treatment of keloid scarring and hypertrophic scarring.

Edit Page Add Page